title: Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
abstract: METHODS
  Prospective randomised clinical trial comparing the safety and efficacy of rifampicin- and thiacetazone-containing regimens in human immunodeficiency virus (HIV)-infected adults with pulmonary tuberculosis (TB) at the National Tuberculosis Treatment Centre, Kampala, Uganda.
  
  
  OBJECTIVE
  To assess demographic, clinical and laboratory risk factors associated with toxicity during treatment with streptomycin, thiacetazone and isoniazid (STH) of HIV-1 infected adults with pulmonary TB.
  
  
  METHODS
  Nested case-control study of all subjects randomized to the STH treatment arm. Baseline demographic, clinical, microbiological, hematological and radiographic characteristics were compared between subjects who developed and those who did not develop adverse drug reactions (ADR).
  
  
  RESULTS
  Of the 90 subjects randomized to STH, 13 developed ADR yielding an incidence rate of 19.6 events per 100 person years of observation (PYO). Eleven of the 13 ADR were cutaneous hypersensitivity reactions, including one fatal case of Stevens-Johnson syndrome. Eight of 13 patients who developed ADR were tuberculin anergic, compared to 12 of 77 patients who did not develop ADR (P < 0.001). An absolute lymphocyte count below 2000 cells/mm3 was also associated with ADR (P = 0.02).
  
  
  CONCLUSIONS
  Initial anergy to tuberculin and lymphocytopenia, markers of advanced HIV infection and immunosuppression, were associated with increased risk for adverse drug reactions during STH chemotherapy.
authors.affiliation: Uganda-Case Western Reserve University Research Collaboration, Kampala, Uganda.
authors.forename: A
authors.initials: A
authors.lastname: Okwera
authors.forename: J L
authors.initials: JL
authors.lastname: Johnson
authors.forename: M J
authors.initials: MJ
authors.lastname: Vjecha
authors.forename: K
authors.initials: K
authors.lastname: Wolski
authors.forename: C C
authors.initials: CC
authors.lastname: Whalen
authors.forename: D
authors.initials: D
authors.lastname: Hom
authors.forename: R
authors.initials: R
authors.lastname: Huebner
authors.forename: R D
authors.initials: RD
authors.lastname: Mugerwa
authors.forename: J J
authors.initials: JJ
authors.lastname: Ellner
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016022:Case-Control Studies; D017635:Clonal Anergy; D016001:Confidence Intervals; D003906:Developing Countries; D003875:Drug Eruptions / Q000453:epidemiology* / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D015497:HIV-1; D006801:Humans; D015994:Incidence; D007565:Jaundice / Q000139:chemically induced; D008231:Lymphopenia / Q000209:etiology; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011446:Prospective Studies; D012293:Rifampin / Q000627:therapeutic use; D012307:Risk Factors; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced; D015996:Survival Rate; D013828:Thioacetazone / Q000009:adverse effects* / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D014454:Uganda / Q000453:epidemiology
chemical_list: D000995:Antitubercular Agents; D013828:Thioacetazone; D012293:Rifampin